FDA approves AstraZeneca's Epanova, label update for Teva's Synribo; Researchers head to Twitter to identify drug problems;

> The FDA has green-lighted AstraZeneca's ($AZN) Epanova as a treatment for severe hypertriglyceridaemia in adults. Release

> The FDA has approved a label change for Teva's ($TEVA) Synribo injection that allows for home administration. Release

> A 6-week marketing suspension on Ariad's ($ARIA) chronic myeloid leukemia drug Iclusig has not negatively impacted how physicians view the drug, a survey found. More

> The U.S. diabetes market will reach $25 billion by 2020, with Sanofi ($SNY), Novo Nordisk ($NVO) and Eli Lilly ($LLY) leading the way, a new report says. Release

> An FDA panel will meet in October to review the risks of psychiatric and behavioral side effects associated with Pfizer's ($PFE) antismoking med Chantix. More

And Finally... Researchers have found that tapping into Twitter to read patient posts describing medication side effects could help them identify problems with drugs sooner. Story

Suggested Articles

Roche’s Tecentriq didn't repeat its prior TNBC success when tested in tandem with chemo med paclitaxel in previously untreated metastatic patients.

Alexion Pharmaceuticals names its first chief diversity officer as the rare disease specialist looks to cultivate diversity and inclusion.

Back in 2015, GlaxoSmithKline traded away its marketed cancer assets and began rebuilding its oncology pipeline. Those efforts have finally paid off.